A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation
Latest Information Update: 28 Aug 2008
Price :
$35 *
At a glance
- Drugs Octreotide (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 11 Aug 2008 Planned end date added as 1 May 2006 as reported by ClinicalTrials.gov.
- 11 Aug 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Nov 2005 New trial record.